You just read:

AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease

News provided by

AbbVie

Sep 25, 2014, 08:00 ET